Publication Information (EuropePMC) | |
Title | Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. |
PubMed ID | 25748612(Europe PMC) |
doi | 10.1016/S0140-6736(14)61730-X |
Publication Date | March 4, 2015 |
Journal | Lancet |
Author(s) | Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. |
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000010 (GRS27) |
PGP000003 | Mega JL et al. Lancet (2015) |
Coronary heart disease | coronary artery disease | 27 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000010/ScoringFiles/PGS000010.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000014 | PGS000010 (GRS27) |
PSS000008| European Ancestry| 42,998 individuals |
PGP000003 | Mega JL et al. Lancet (2015) |
Reported Trait: Coronary heart disease | HR: 1.21 [1.17, 1.26] | — | — | age, sex, diabetes status, smoking, race, family history of coronary heart disease, HDL cholesterol, LDL cholesterol, and hypertension | Meta-analysis of sub-cohort effect sizes |
PPM000015 | PGS000010 (GRS27) |
PSS000009| European Ancestry| 4,877 individuals |
PGP000003 | Mega JL et al. Lancet (2015) |
Reported Trait: Coronary heart disease | HR: 1.14 [1.02, 1.28] | — | — | age, sex, diabetes status, smoking, race, family history of coronary heart disease, HDL cholesterol, LDL cholesterol, and hypertension | Meta-analysis of sub-cohort effect sizes |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000008 | Coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention | — | [ ,
79.7 % Male samples |
— | European | — | ASCOT | Primary prevention cohorts |
PSS000009 | Coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention | — | [ ,
86.1 % Male samples |
— | European | — | CARE_b | Secondary prevention cohorts |
PSS000009 | Coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention | — | [ ,
77.5 % Male samples |
— | European | — | PROVEIT | Secondary prevention cohorts |
PSS000008 | Coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention | — | 27,271 individuals, 38.7 % Male samples |
— | European (Swedish) |
— | MDC | Primary prevention cohorts |
PSS000008 | Coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention | — | [ ,
67.8 % Male samples |
— | European | — | JUPITER | Primary prevention cohorts |